Abstract
Between 1985 and 1992, 56 patients with unresectable liver metastases from breast cancer were treated by repeated hepatic arterial infusion chemotherapy employing an implantable port system. 5-Fluorouracil (5-FU) at 330 mg/m2 per week, Adriamycin (ADR) at 20 mg/m2 every 4 weeks, and mitomycin C (MMC) at 2.7 mg/m2 every 2 weeks were given to 42 patients. The remaining 14 patients received 5-FU at 330 mg/m2 per week and epirubicin (EPIR) at 20 mg/m2 every 2 weeks. As a rule, the treatment was performed on an outpatient basis. The side effects and complications observed included myelosuppression (41%), hepatic arterial occlusion (23%), and gastric mucositis (20%), but no major toxicity was encountered. The response rate (CR+PR) of the evaluated patients as determined from CT scans was 81%. The overall median survival period was 12.5 months. Only 14% of the patients died due to regrowth of liver metastases, and in 70% of the total cases, death due to liver metastases was avoided by this treatment. Thus, repeated hepatic arterial infusion chemotherapy for liver metastases from breast cancer might be capable of prolonging the survival of patients via avoidance of death due to the liver metastases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arai Y, Kido C, Endo T, Fukushima M (1988) Hepatic arterial infusion chemotherapy for liver metastasis from colon, gastric and breast cancer. Proc Am Soc Clin Oncol 7: 102
Arai Y, Endo T, Miyake Y, Ariyoshi Y (1990) A study of technical problems in hepatic arterial infusion chemotherapy using percutaneous approach. Jpn J Med Imaging 9: 114
Aria Y, Endo T, Sone Y, Tohyama N, Inaba Y, Kohno S, Ariyoshi Y Kido C (1992) Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system. Cancer Chemother Pharmacol 31: [Suppl 1]: S99
Chuang VP, Wallace S (1980) Hepatic arterial redistribution for intraarterial infusion of hepatic neoplasms. Radiology 135: 295
Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, Amadori D, Giovanelli E (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. Cancer 51: 581
Fraschini G, Fleishman G, Charnsangavej C, Carrasco CH, Hortobagyi GN (1987) Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer. Cancer Treat Rep 71: 1001
Fraschini G, Charnsangavej C, Carrasco CH, Buzdar AU, Jabboury KW, Hortobagyi GN (1988) Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol 11: 34
Henderson IC (1990) Chemotherapy for advanced disease, ch 13. Treatment of metastasis. In: De Vita VT (ed) Cancer treatment. J. B. Lippincott, Philadelphia, p 428
Hortobagyi GN, Guttermann JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM (1979) Combination chemoimmunotherapy of metasstatic breast cancer with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG. Cancer 43: 1225
Inoue K, Ogawa M, Horikoshi N, Aiba K, Mukaiyama T, Mizunuma N, Itami S, Hirano A, Matsuoka A, Matsumura T (1991) Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer. Jpn J Clin Oncol 21: 334
Jones SE, Durie BGM, Salmon SE (1975) Combination chemotherapy with Adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36: 90
Kitamura M, Tominaga T, Hayashi K, Shimozuma K, Kosaki G (1988) The effect of systemic chemotherapy for advanced breast cancer with liver metastases — systemic chemotherapy. Jpn J Clin Breast Cancer 3: 379
Leonard RC, Cornbleet MA, Kaye SB, Soukop M, White G, Hutchen AW, Robinson S, Kerr ME, Smyth JF (1987) Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J Clin Oncol 5: 1056
Reed ML, Vaitkevicius VK, Al-Sarraf M, Vaughn CB, Singhakowinta A, Sexon-Porte M, Izbicki R, Baker L, Straatsma GW (1981) The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer 47: 402
Tranum B, Hoogstraten B, Kennedy A, Vaughn CB, Samal B, Thigpen T, Rivkin S, Smith F, Palmer RL, Costanzi J, Tucker WG, Wilson H, Maloney TR (1978) Adriamycin in combination for the treatment of breast cancer. A Southwest Oncology Group study. Cancer 41: 2078
Tranum BL, McDonald B, Thigpen T, Vaughn C, Wilson H, Maloney T, Costanzi J, Bickers J, Gad el Mawli N, Palmer R, Hoogstraten B, Heilburn L, Rasmusen S (1982) Adriamycin combination in advanced breast cancer. A Southwest Oncology Group study. Cancer 49: 835
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arai, Y., Sone, Y., Inaba, Y. et al. Hepatic arterial infusion chemotherapy for liver metastases from breast cancer. Cancer Chemother. Pharmacol. 33 (Suppl 1), S142–S144 (1994). https://doi.org/10.1007/BF00686687
Issue Date:
DOI: https://doi.org/10.1007/BF00686687